This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petersen, J. R. Articles by Winther, K. Search for Related Content PubMed PubMed Citation Articles by Petersen, J. R. Articles by Winther, K. Social Bookmarking                         What's this?

ACE Inhibition with Spirapril Improves Diastolic Function at Rest Independent of Vasodilation During Treatment with Spirapril in Mild to Moderate Hypertension

Department of Clinical Physiology, Frederiksberg Hospital, Frederiksberg

Hans Drabaek, M.D.

Department of Clinical Physiology, Frederiksberg Hospital, Frederiksberg

Gitte Gleerup, M.D.

Department of Cardiology, Gentofte Hospital, Hellerup

Jesper Mehlsen, M.D., F.A.C.A.

Department of Clinical Physiology, Frederiksberg Hospital, Frederiksberg

Lars Juhl Petersen, M.D.

Department of Nephrology, Hvidovre Hospital, Hvidovre

Kaj Winther, M.D.

Department of Clinical Chemistry, Glostrup Hospital, Glostrup, Denmark

The effects of the ACE inhibitor spirapril and of hydrochlorothiazide on left ventricular diastolic function were studied. Thirteen patients with mild to moderate essential hypertension completed this randomized, double-blinded, placebo-controlled, crossover study. After a three-week run-in period the patients entered three periods lasting four weeks each, wherein they were treated with placebo, spirapril, or hydrochlorothiazide. Blood pressure, hemodynamic variables (stroke volume, heart rate, cardiac output, index of contractility, and systemic vascular resistance), echocardiography (left ventricular mass), and Doppler-derived atrial to early (A/E)-ratio velocity time integrals (VTI) were measured at the end of each of the four periods.

Spirapril lowered the A/E-ratio VTIs (0.57, 0.12-1.00) (P < 0.02) as compared with both placebo (0.80, 0.50-2.67) and hydrochlorothiazide (0.83, 0.44-1.25), and the drug normalized the A/E-ratio VTI in those patients with elevated values. The hemodynamic variables, left ventricular mass, and end-systolic wall stress were unchanged during all three treatments. There were no significant changes in mean blood pressure during the treatment periods.

These results indicate that spirapril lowers A/E ratio within four weeks in patients with mild to moderate essential hypertension. It thereby seems able to improve left ventricular diastolic function. The effect is not dependent upon changes in hemodynamic variables, blood pressure, left ventricular mass, or end-systolic wall stress.

Angiology, Vol. 47, No. 3, 233-240 (1996)
DOI: 10.1177/000331979604700303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?